676445-27-5

Usage

Iodine content

Two atoms of iodine; the presence of iodine gives the compound its reactivity and potential applications in various fields.

Fluorine content

Six atoms of fluorine; the fluorine atoms contribute to the compound's stability and unique chemical properties.

Formamide content

One atom of formamide; the formamide group provides a functional group for further chemical reactions and modifications.

Usage in organic synthesis

Acts as a building block in the creation of various compounds, making it a valuable tool in the development of new materials and compounds with diverse properties.

Role as a chemical intermediate

Used in the production of pharmaceuticals; this highlights its importance in the synthesis of various drugs and medications.

Versatility in chemical reactions

Known for its ability to participate in a wide range of chemical reactions, making it a useful compound in various research and development settings.

Upstream product

• 111771-12-1 2-fluoro-6-iodobenzoyl chloride 
• 111771-08-5 2-fluoro-6-iodobenzoic acid 

Downstream Products

• 578729-12-1 5-(2-fluoro-6-iodophenyl)-3-methyl-1,2,4-oxadiazole 
• 1221408-05-4 C₁₀H₁₁IN₂O 
• 1048960-67-3 tert-butyl (1R)-1-[3,3'-difluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)-1,1'-biphenyl-4-yl]-ethylcarbamate 

Relevant academic research and scientific papers

Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents

Agonists of the 5-HT2C receptor have been shown to suppress appetite and reduce body weight in animal models as well as in humans. However, agonism of the related 5-HT2B receptor has been associated with valvular heart disease. Synthesis and biological evaluation of a series of novel and highly selective dihydroquinazolinone-derived 5-HT2C agonists with no detectable agonism of the 5-HT2B receptor is described. Among these, compounds (+)-2a and (+)-3c were identified as potent and highly selective agonists which exhibited weight loss in a rat model upon oral dosing.

Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists

A series of biphenylaminocyclopropane carboxamide based bradykinin B 1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in t

2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridine derivatives

Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.